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Abstract
Fatalities caused by parasitic infections often occur as a result of tissue injury that results from a form of host-cell
death known as apoptosis. However, instead of being pathogenic, parasite-induced apoptosis may facilitate host
survival. Consequently, it is of utmost importance to decipher and understand the process and the role of apopto-
sis induced or controlled by parasites in humans. Despite this, few studies provide definitive knowledge of parasite-
induced host-cell apoptosis. Here, the focus is on a consideration of host-cell apoptosis as either a pathogenic fea-
ture or as a factor enabling parasite survival and development.
Cell death by apoptotic-like mechanisms could be described as a ride to death with a return ticket, as initiation of
the pathway may be reversed, with the potential that it could be manipulated for therapeutic purposes. The man-
agement of host-cell apoptosis could thus be an adjunctive factor for parasitic disease treatment. Evidence that the
apoptotic process could be reversed by anti-apoptotic drugs has recently been obtained, leading to the possibility
of host-cell rescue after injury. An important issue will be to predict the beneficial or deleterious effects of control-
ling human cell death by apoptotic-like mechanisms during parasitic diseases.
Apoptosis modulation: harmful or helpful?
Apoptosis is a form of programmed cell death involved
in a wide range of adaptive processes, from embryogen-
esis to stress injury responses. The main benefits of
apoptosis occur when an organism is uninfected. How-
ever, detrimental effects caused by apoptosis can be trig-
gered by parasitic infection, depending upon the specific
host-parasite situation. During their evolution, parasites
have developed mechanisms to induce or avoid host cell
apoptosis in order to be able to survive and complete
their life cycle.
Pathways involved in apoptosis are highly regulated,
demonstrating that this mechanism is finely tuned
according to the biological environment of the cell.
Among the factors involved in that balance in infected
organisms, the time of apoptosis (early or late occur-
rence), the cell type and the type of parasitism (intracel-
lular or not) are the major modulators. For example,
early apoptosis of host cells could contribute towards
their fight against infection by intracellular parasites;
equally, early apoptosis could favour the penetration of
the parasite. Late apoptosis of cells of the defence sys-
tem could be beneficial to the host, clearing excess cells
and thereby avoiding the detrimental effects of excessive
inflammatory response in the tissue that they would
cause (e.g. the deleterious effect of reactive oxygen spe-
cies or pro-inflammatory cytokines triggered by Plasmo-
dium in the liver) [1]. This could also be beneficial for
the parasite, by limiting the potential for the host to
develop a protective immune response.
A major issue that has not yet been addressed by
experimental data is the helpful/harmful ratio obtained
with anti-apoptotic treatment during infection. Since
apoptosis pathways are common to almost all human
cells, it could be speculated that protective adjuvant
therapy using anti-apoptotic drug would have a benefi-
cial action on damaged cells but, at the same time, it
could also induce deleterious effects on tissues where
apoptosis was necessary for cell homeostasis. One other
option could be to favour apoptosis of the infected cell.
What would be the effect of this treatment on non-
infected cells? Treatment devoted to the induction of
infected-cell apoptosis, for example to avoid the disse-
mination of intracellular parasites, could also be respon-
sible for detrimental effects on non-infected cells.
Would this increase the aging of normal cells? As yet,
there is no evidence for a risk, but these major points
should be kept in mind before using a pro-apoptotic
treatment.
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When should cell death be called apoptosis?
During the last decade, descriptions of cell death
induced by pathogens increased very rapidly. However,
cell death is a very complex phenomenon and descrip-
tions were, in many cases, based on methods available
in a particular laboratory rather than standardized meth-
ods. None of the single morphological, enzymatic or
functional aspects of cell death provide a definitive
proof that observed cell death should be considered as
apoptosis. While a first round of recommendations was
published in 2005 [2], a more accurate classification of
cell death has been available since late 2008 [3]. It
should be mentioned that almost none of the papers
reviewed here use the recent classification. A number of
cited publications mentioned the use of only one
method to explore cell death, and in most cases it is
extrapolated from this evidence to be “apoptosis”. It
should also be kept in mind that cell death could display
mixed features and that events observed in a tissue col-
lected post-mortem or a cell culture in vitro are probably
not perfectly representative of the in vivo physiology.
The inflation of terms used to describe cell death is not
related to the same inflation of knowledge on pathologi-
cal mechanisms. Since it was unrealistic to analyze the
published literature with regard to the recent classifica-
tion system, author’s definitions of apoptosis as the
mode of cell death that they have observed should be
used with caution.
Here, apoptosis of host cells during parasitic disease
and its potential association with clinical features will be
reviewed. Apoptosis of host immune cells will not be
considered in this review.
Apoptosis of Endothelial cells
Severe malaria is responsible for an unacceptable mor-
tality rate, despite efficient anti-malaria treatment. One
explanation for this case fatality rate is host-cell apopto-
sis induced by the parasite, which could lead to irrever-
sible tissue injuries. Endothelial cells are key players in
the pathophysiology of severe disease. Parasitized red
blood cells (PRBC) circulating within microvasculature
induce a pro-inflammatory cascade leading to activation
of endothelial cells. One of the early phenomena occur-
ring in that process is the over-expression of ICAM-1
receptors by endothelial cells (EC) stimulated by the
parasite [4]. This leads to parasitized red blood cell
(PRBC) adhesion to endothelial cells. Concomitant
expression of iNOS results in PRBC sequestration and
finally caspase 8 and 9 dependent apoptosis in endothe-
lial cells (EC) [5]. This endothelial cell apoptosis leads
to blood-brain-barrier disruption and contributes to the
development of cerebral malaria [6]. Authors compared
human brains collected post mortem after cerebral
malaria (CM) with brains collected after death from
non-malarial causes [7]. Using immunochemistry meth-
ods, they observed a generalized reduction of cell junc-
tion proteins (occludin, vinculin, ZO-1) in the brain of
patients who died of CM. More recently, it was demon-
strated that PRBC adherence to host endothelium is not
a prerequisite for inducing apoptosis as sera from
malaria patients induced endothelial apoptosis [8]. In
addition, Plasmodium falciparum field isolates from
patients presenting neurological signs can induce EC
apoptosis [9] and a soluble apoptotic factor from PRBC
could have apoptogenic effects on human brain
endothelial and neuroglial cells [10]. Finally, the Rho
kinase pathway could be involved in pathogenic interac-
tions between endothelium and P. falciparum during
CM [11]. Indeed, fasudil, a Rho kinase inhibitor, restores
endothelial barrier integrity after exposure of human
lung endothelial cells to PRBCs in vitro.
While the deleterious effect of brain perivascular
oedema and ring haemorrhages are well known, deci-
phering the exact role that Plasmodium-induced
endothelial cell-apoptosis plays in CM could help in
understanding discrepancies amongst patients living in
the same conditions but presenting either severe or
non-severe malaria. It may provide a new understanding
on the difference in the severity of disease induced by
P. falciparum compared to P. vivax, P. ovale or P.
malariae. It will also provide a good opportunity for
assessment of treatment devoted to the protection of
that non specific, but highly regulated, mechanism of
endothelial cell death.
Transmitted by the bite of tsetse flies, human african
trypanosomiasis (HAT), also known as sleeping sickness,
develops after Trypanosoma brucei has invaded the cen-
tral nervous system. This infection causes neuronal
demyelination and apoptosis after blood-brain barrier
rupture. The damage to brain microvascular endothelial
cells is driven by a parasite-derived factor which is
released into the bloodstream and cerebrospinal fluid
(CSF) during peak parasitaemia and leads to apoptosis
in cells of the cerebellum and brain-stem, as demon-
strated by terminal deoxynucleotidyl transferase dUTP
nick end labelling (TUNEL). The trypanosoma-derived
factor was partially characterized and a synthetic peptide
made which induces similar apoptosis in vitro [12].
Moreover, CSF collected from patients with HAT
induced apoptosis in endothelial and microglial cells in
vitro and contains sFasL and anti-Fas antibodies at
higher levels than controls, providing candidate markers
of blood-brain barrier disruption [13].
Acute myocarditis is a frequent complication of Cha-
gas disease, caused by Trypanosoma cruzi. Cardiac
microvasculature alterations, with the formation of
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microthrombi, were demonstrated in acute cases [14].
However, while apoptosis of endothelial cells occurs, it
seems to be infrequent and not associated with invasion
of endothelial cells by the parasite. Mediators of inflam-
mation, including reactive oxygen species, are suspected
to be involved in this phenomenon [15].
Apoptosis of cardiomyocytes
Apoptosis of cardiomyocytes was previously reported
during ischemia-reperfusion in vivo, myocardial infarc-
tion [16] and many acute and chronic diseases affecting
the heart. Few parasitic diseases lead to cardiac dysfunc-
tion and the most relevant is certainly Chagas disease.
Infection by T. cruzi leads to multi-organ disease and
acute myocarditis is prominent. Cardiac muscle cells are
invaded by the parasite, allowing parasite differentiation
and multiplication. The occurrence of cardiomyocyte-
apoptosis has been demonstrated experimentally.
Using a canine model of acute chagasic myocarditis,
apoptosis (identified by TUNEL) was found in non-
infected T. cruzi cardiomyocytes in close proximity to
mononuclear inflammatory cells and was probably
caused by the release of toxic mediator of inflamma-
tion [14,15]. In these investigations, infected cardio-
myocytes did not show evidence for apoptosis as
measured by TUNEL, but contradictory data were
obtained later [17]. Authors of the latter study specu-
lated that apoptosis of cardiomyocytes is not induced
by a mediator of inflammation but by previously
described transialidases produced by the parasites.
Since there are several lines of evidence that T. cruzi is
able to up- or down-regulate apoptosis of fibroblasts
and macrophages, these findings provide more support
to the hypothesis that heart injury during Chagas dis-
ease is not only caused by direct invasion of cardio-
myocytes by parasites, but by a more complex host-
parasite relationship. These authors also related the
role of apoptosis in the pathogenesis of the disease to
the clone of parasite and their different abilities to
invade and proliferate within host cells [17].
The degree to which apoptosis of myocytes occurred
during the disease is variable in size and distribution.
Using heart samples from chagasic patients, cardiomyo-
cyte-apoptosis was shown and associated with heart fail-
ure [18]. It was demonstrated later that an increase in
the level of Fas-FasL regulates the extent of cardiac
inflammation, cardiomyocytes destruction and heart fail-
ure in Chagas disease patients [19,20].
Chagas disease is more chronic than severe malaria,
and host cells apoptosis seems to play a different role in
the pathology. While infected cells may be partly pro-
tected from death, an apoptotic signal is sent to neigh-
bouring cells, extending the area of cardiac cell death.
Our knowledge of the exact mechanisms of that process
is far from complete, but it could be speculated that,
with further understanding, the inhibition of this apop-
tosis could be a cornerstone in the prevention of heart
failures for chagasic patients.
Severe malaria is associated with PRBC sequestration
in brain vessels, but this phenomenon is also reported
in other organs, including lung, kidney and heart
[21,22]. However, the relationship between sequestration
and tissue injury is weak in most of these cases. Heart
failures have been noticed in very few cases of severe
malaria, with no clear relevance of a pro-apoptotic effect
caused by the parasite.
More recently, glycosylphosphatidylinositols (GPIs), a
class of glycolipids with various functions, was suspected
to be involved in cardiomyocyte death [23]. P. falci-
parum GPI (Pf-GPI) failed to induce myocardiocyte-
apoptosis in vitro. Pf-GPI injected in vivo led to the
occurrence of apoptotic cells in liver and spleen tissue.
Gene expression analysis of Pf-GPI-treated cardiomyo-
cytes showed an up-regulation of both apoptotic genes
(apaf-1, bax) and a myocardial damage marker (brain
natriuretic peptide), while a down-regulation for the
anti-apoptotic gene (bcl-2) was observed [24].
Apoptosis of neuronal cells
After brain blood barrier (BBB) disruption caused by
endothelial cell-apoptosis, oedema and perivascular hae-
morrhages are responsible for neuronal cell injury.
Axons are the most susceptible to ischemic or toxic
damage in different brain areas, and axonal injury
detected by elevated CSF levels of tau protein and S-
100B (markers of axonal damage) were observed during
cerebral malaria in Kenyan children [25]. These authors
demonstrated that seizures after admission are a mani-
festation of brain damage, rather than a cause.
Cognitive deficit is seen during CM and it could be
related to astrocytes and microglia cell death. It is sus-
pected that Fas-Fas ligand could be involved in brain-
cell apoptosis. In wild type mice, Fas ligand positive
cells are localized around the vasculature and particu-
larly in the olfactory bulb. Moreover, Lpr (lymphoproli-
feration spontaneous mutation) and Gld (generalized
lymphoproliferative disease) mice, that have mutations
in Fas and Fasl, respectively, are resistant to experimen-
tal cerebral malaria despite high parasitaemia levels and
brain petechial haemorrhages [26]. This is in contradic-
tion with a previous study reporting that Lpr and Gld
mice were susceptible to cerebral malaria [27]. Brains of
terminally ill infected mice showed apoptosis of neuro-
nal cells, as detected by TUNEL and caspase 3 antibody
binding [28]. Activated caspase 3 detected in brain
extracts is correlated with the clinical severity of the dis-
ease [29]. Activated caspase 3 was mainly detected in
neurons and oligodendrocytes in terminally ill animals,
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leading authors to suggest that these cells are the most
vulnerable to apoptosis.
Clearly, many aspects of the pathogenesis of cerebral
malaria are still unknown. It could be speculated that
the role of apoptosis was underestimated in the past,
and should warrant more attention in the future.
In T. brucei-infections, the invasion of the central ner-
vous system by the parasite induces a meningo-encepha-
litis with BBB disruption and neuronal demyelinisation.
Scattered small-cell apoptosis was found in the brain of
rats infected with T. brucei, as well as degeneration of
nerve fibres [30].
In humans, extensive cerebellum and brain-stem
apoptosis (detected by TUNEL) was demonstrated, as
was injury in the locus ceruleus, which is responsible for
the modification of sleep and wakefulness characteristic
of the disease [13,31]. The parasite’s entry into host tis-
sue is mediated by the production of a parasite-derived
factor (TAF) which induces endothelial cell-apoptosis
and damage to the vascular endothelium. This patho-
genic factor, identified by Surface Enhanced Laser Deso-
rption Ionization (SELDI), could be responsible for the
destruction of immune cells and apoptosis of brain cells
at peak parasitemia [31]. This pro-apoptotic parasitic
factor is released in the CSF of patients
Cerebral toxoplasmosis is a severe complication of
Toxoplasma infection observed in immunosuppressed
people and AIDS patients and is associated with a high
mortality rate. Few studies have addressed the question
of the role of host cell apoptosis in the brain during tox-
oplasmosis, while more data are available from retina
studies. In an experimental model of acquired ocular
toxoplasmosis, wild type, lpr and gld mice, all showed a
mild to moderate encephalitis with focal necrosis, cere-
bral vascularitis and meningitidis at day 14, and a mod-
erate to severe disease at day 28 after inoculation [32].
Among the inflammatory cells, TUNEL positive cells
were observed in all groups of mice. Expression of Fas/
FasL was enhanced in the brain, 28 days after inocula-
tion of wild-type mice with Toxoplasma gondii. As
expected, this expression was absent in lpr and gld
mice. Cerebral toxoplasmosis may be partially explained
by Fas/FasL-mediated apoptosis. Other pathways are
suspected to be involved in apoptosis, as demonstrated
by TUNEL positive cells in the brains of lpr and gld
mice.
Apoptosis of hepatocytes
Infection of hepatocytes after sporozoite transmission to
humans by mosquito bites is a crucial step for malaria
infection. The relationship between parasites and hepa-
tocytes is complex. It was recently demonstrated that
Kupffer cells were TUNEL positive after incubation in
vitro with sporozoites, suggesting that P. yoelii
sporozoites caused apoptosis of Kupffer cells [1]. This
apoptosis limits the local production of cytokines and
the activation of the immune system. However, to sur-
vive and develop within hepatocytes, Plasmodium para-
sites have developed the capability to inhibit host cell
apoptosis [33]. Hepatocytes damage induces the release
of hepatocyte growth factor [34] mediating the inhibi-
tion of the death of infected hepatocytes.
When HepG2 liver cells are infected with P. berghei,
cells are protected from peroxide injury, whilst non
infected HepG2 cells undergo apoptosis [35]. This was
confirmed by the demonstration that infected cells con-
taining viable parasites are protected from apoptosis,
whereas hepatocytes containing dead parasites are no
longer protected from cell death. The levels of Fas
expression and caspase 8 activities are the same in
infected and uninfected liver cells of mice, but hydroxyl
radicals are increased in infected mice [36]. The contri-
bution of oxidative stress to hepatocytes apoptosis has
also been demonstrated using melatonin, a non toxic
anti-apoptotic and anti-oxidant molecule [37]; melatonin
prevents hepatocytes from undergoing apoptosis in
mice, as demonstrated by caspase 3 and TUNEL assays.
After parasites have been released from hepatocytes,
they invade red blood cells for the erythrocytic multipli-
cation phase. During that stage of the infection, Plasmo-
dium degrades huge quantities of haemoglobin to
produce heme and haemozoin which are deleterious.
Haemozoin can be deposited in the liver, where it is
responsible for an oxidative insult [38]. Inside the cyto-
sol, heme is degraded by haem oxygenase 1 (HO-1)
which causes the release of iron inside the cell. The
existence of high levels of free iron and H2O2 inside
mitochondria favours the generation of highly toxic °
OH, oxidation of mitochondrial lipids, release of cyto-
chrome c into the cytosol, and activation of caspase 9/
caspase 3 to execute hepatocyte apoptosis. BALB/c mice
deficient in haem oxygenase are killed by Plasmodium
chabaudi chabaudi infection [39], irrespective to the
level of parasitaemia. These mice developed hepatic fail-
ure but not cerebral malaria or other forms of severe
malaria. DBA/2 mice also succumb to P. c. chabaudi
infection with hepatic failure. Transduction of these
mice with a vector expressing HO-1 limits the hepatic
injury and avoids the mortality [39]. The same study
showed that when exposed to free haem plus TNF, hall-
marks of apoptosis are detected in hepatocytes in vitro.
Data obtained from these different models of malaria
demonstrate the high level of complexity of the relation-
ship between Plasmodium and hepatocytes, and the
need for more research.
The late stage of hepatocytes invasion involves the
release of parasites into the blood stream. This release
occurs following the rupture of the parasitophorous
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vacuole membrane, and leads to hepatocytes cell death
[40]. This hepatocytes cell death contributes to the for-
mation of merosomes and their budding through the
endothelium into the blood vessel.
In malaria infections the liver is consider more as an
asymptomatic reservoir of parasites during the early
phases of the disease rather than a target for pathogenic
mechanisms. Researches dedicated to an understanding
of hepatocytes-apoptosis could lead to useful informa-
tion for designing vaccination programmes against
P. falciparum sporozoites and for prevention of Plasmo-
dium vivax hypnozoites recrudescence.
Entamoeba histolytica destroys intestinal cells by the
release of proteolytic enzymes and then triggers a host
inflammatory response in the liver. This response is
believed to contribute to tissue damage and abscess for-
mation. More than a decade ago, authors raised the
question of whether parasites-induced necrosis or apop-
tosis of liver cells occurred as a result. After publication
of controversial data [41] a severe, combined immuno-
deficient mouse model of amoebic liver abscess was
used to demonstrate that E. histolytica induces TUNEL
positive cell death and DNA fragmentation in amoebic
liver abscesses [42]. This cell death was not reduced in
mice with point mutations in the gld gene resulting in
the expression of non-functional Fas ligand, nor in mice
lacking TNFR1, demonstrating that TNF alpha and Fas/
Fas ligand pathways are not involved.
The role of apoptotic cell death was also documented
by the treatment of mice with a caspase inhibitor (Z-
VAD-fmk) prior to infection with E. histolytica [43].
Amoebic liver abscesses were significantly smaller in
mice receiving the caspase inhibitor, with less TUNEL
positive hepatocytes and less DNA laddering in the
abscesses. However, during a transcriptional analysis of
the response of mouse liver to E. histolytica infection,
81 apoptosis-related genes exhibited transcriptional
changes in amoebic liver abscess, 46 were pro-apoptotic
[44]. Increased expression of the gene encoding the pro-
apoptosis receptor Fas and genes downstream of Fas sig-
nalling, as well as genes linked to the TNF receptor
pathways, were detected.
Using engineered parasites (HGL-2 trophozoïtes) pre-
senting a disruption of Gal/GalNAc lectin, authors
recently tested the hypothesis that adhesion molecules are
linked to liver cell death and the pathophysiology of amoe-
bic abscess. TUNEL analysis of liver cells from infected
hamsters showed more TUNEL positive hepatocytes dur-
ing infection with adherent parasite than with lectin defi-
cient parasite [45]. The decrease in adherence and
mobility of the parasite was correlated with a decrease in
inflammatory response and local liver cell death.
Biliary tract injury associated with infection by
the Asian fluke Clonorchis sinensis could lead to
cholangiocarcinoma. Cell death involving TUNEL-posi-
tive hepatocytes was found in tissue around the central
vein or portal areas or rats infected with high parasite
loads [46]. Whether this cell death was induced by fac-
tors released by the parasite or by inflammatory cells is
unknown. The expression of Fas, FasL and caspase
3 mRNA was increased in infected livers. Liver cell
death induced by C. sinensis may contribute to clinical
manifestations in patients.
Apoptosis in the eye
Toxoplasmosis is a benign disease except during preg-
nancy and immunosuppression, however, it could be
responsible for ocular disease, mostly necrotizing retini-
tis and retinochoroiditis. It has been hypothesised that
apoptosis and Fas/FasL pathways could be involved in
ocular toxoplasmosis. To test this, lpr mice and gld
mice which have defective Fas and FasL expressions
respectively, were used [32,47]. A greater number of
TUNEL positive cells were observed in the anterior
chamber and in vitreous humour of wild-type mice after
intraocular infection compared to lpr and gld deficient
mice. Fas and FasL expression was increased in the eyes
of infected wild-type mice compared to non infected
mice [47].
Acanthamoeba keratitis is an infection of the ocular
surface that produces pain and ulceration. It involves
sequential events including production of pathogenic
proteases that degrade membranes and induce cytolysis
and apoptosis of cornea cells [48]. After adhesion of tro-
phozoïtes to the corneal epithelial cells, Acanthamoeba
secretes proteases that enable the amoebae to penetrate
corneal tissue: mannose-induced protein 133 (MIP 133)
produces contact-independent cytolysis of corneal
epithelial cells in vitro and facilitates destruction of the
corneal epithelium [49]. Acanthamoeba can also use
plasminogen activators to catalyse the cleavage of host
plasminogen to form plasmin. Then, plasmin can acti-
vate proteases, such as matrix metalloproteinase (MMP)
that can degrade components of the extracellular matrix
[50] and this process is involved in the observed corneal
ulceration [51].
Malarial retinopathy occurs in 60% of children suffer-
ing cerebral malaria, with a high fatality rate [52].
During cerebral malaria in humans, pathological exami-
nation of eyes post-mortem showed parasites sequestered
in the retinal vasculature and haemorrhages that were
similar to ring haemorrhages seen in the brain and asso-
ciated with thrombi, and rupture of the blood-retinal-
barrier [53]. Due to these similarities between the retina
and the brain injury it may be speculated that apoptosis
would also be detected in the eye. Evidence of apoptosis
in the retina was provided in an experimental model of
cerebral malaria. In retinas of wild-type cerebral-malaria
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mice, it was shown that microglial cells are TUNEL
positive and that astrocytes are caspase-3 positive at day
6 post-infection. In contrast, in lpr and gld deficient
mice, no apoptosis was observed in the retina after Plas-
modium infection.
These observations of ocular damage induced during
parasitic diseases, mainly due to toxoplasmosis and
malaria infection, could provide evidence for concomi-
tant or future cerebral damage. This could help target
more accurately patients who would need more inten-
sive treatments to fight future complications of the
diseases.
Apoptosis in the Skin
The expression of Fas in mice skin tissue was reduced
in chronically infected animals. This could explain the
progression of the lesion in animals [54]. During
L. major infection, apoptosis in keratinocytes was mainly
observed in the superficial epidermis of active and heal-
ing skin samples from patients [55]. Fas expression was
increased in the superficial epidermis of active samples
whereas, in healing and healthy patients, Fas was not
increased. Fas-L expression was mainly found in macro-
phages and T cells of active samples. Fas-L expression
of macrophages and T cells may induce apoptosis and
contribute to ulcer formation in Fas-expressing kerati-
nocytes during L. major infection.
Apoptosis of Erythrocytes
Intra-erythrocytic parasite development is dependant on
the capability of erythrocytes to tolerate parasite inva-
sion and multiplication as this will contribute to an
increase in parasitaemia. Intra-erythrocytic parasites age
their host cells. They induce a dramatic acceleration of
normal erythrocyte senescence which contributes to the
clearance of infected cells. The intra-erythrocytic para-
sites have the challenge of delaying the execution of ery-
throcyte apoptosis: P. falciparum sequesters calcium,
decreases the colloid osmotic pressure of the erythrocy-
tic cytosol and decreases phosphatidylserine exposure
[56].
Phosphatidylserine exposure is an “eat me” signal for
trophozoite infected erythrocytes leading to their phago-
cytic clearance thus inhibition of its exposure contri-
butes to partial immune evasion.
When apoptosis of erythrocytes occurs it leads to hae-
mozoin discharge. The direct effect of haemozoin on
erythroid precursors has been demonstrated [57]. Hae-
mozoin increases levels of reactive oxygen species and
of apoptosis in erythroblasts that are responsible for
inhibition of erythroid expansion. Activation of caspase
8, 9 and 3 and mitochondrial potential disruption, were
observed in erythroblasts, implicating both extrinsic and
intrinsic pathways in the execution of apoptosis.
However, macrophages can protect erythroblasts from
the inhibitory effects of haemozoin [57]. In the absence
of inflammatory mediators and macrophages, accumula-
tion of haemozoin in bone marrow could contribute to
the severity of anaemia in children with chronic malarial
infection.
Apoptosis in the bowel
Cryptosporidium parvum induces apoptosis in intestinal
and biliary epithelial cells in vitro [58]. Apoptosis is
induced by Fas and FasL protein expression, leading to
caspase activation and cleavage of structural target pro-
teins. C. parvum can also prevent apoptosis through
increase activity of NF-kB [59].
Trichinella spiralis induces apoptosis in the lamina
propria of the small intestine and also in striated muscle
[60]. Apoptosis in the intestinal cells is independent of
the number of Trichuris muris. Neutralization of IFN
gamma and TNF alpha causes a significant reduction in
apoptosis, suggesting proinflammatory cytokines may
play a positive role by promoting intestinal epithelial-
cell apoptosis that limits infection-induced epithelial
hyperplasia [61].
Apoptosis targeting: a therapeutic opportunity
for the future?
It is now clear that almost all parasitic diseases induce
host-cell death, leading to tissue damage. It is well
known that ischemic injury results in necrotic cell death
in tissue, surrounded by apoptosis-like cell death in the
area named the “ischemic penumbra”. In that area,
some lines of evidence were recently provided showing
that the apoptotic process could be reversed by anti-
apoptotic drugs leading to the opportunity to rescue
cells. These observations open new doors for tissue pro-
tective therapies that avoid or control these deleterious
processes [62].
The idea of tissue protection was first successfully
explored during experimental and human ischemic
stroke. A double-blind, placebo-controlled, randomized
trial was conducted on patients suffering from a stroke
and demonstrated that high doses of erythropoietin
(Epo) (33 000 IU/day during 3 days) was well tolerated
and safe [63]. Systemic administration of exogenous Epo
regulates cerebral blood flow, protects endothelial cells
against oxidative stress, enhances neurogenesis and
angiogenesis and reduces inflammation by inhibiting
pro-inflammatory cytokines [62]. These effects are partly
due to the inhibition of cellular apoptosis [64]. Interest-
ingly, Epo treatment can be initiated in the first 24
hours after initiation of the lesion [65].
To date, very few studies have been dedicated to these
anti-apoptotic interventions during parasitic diseases
and some anti-apoptotic approaches tested in
Bienvenu et al. Parasites & Vectors 2010, 3:106
http://www.parasitesandvectors.com/content/3/1/106
Page 6 of 9
experimental parasitic diseases, were unsuccessful. For
example, treatment with z-VAD, a pan-caspase inhibitor,
and overexpression of Bcl-2 in transgenic mice, failed to
reduce mortality in experimental cerebral malaria [66].
However, some antiapoptotic interventions in parasitic
disease were proven to be more successful. In a mouse
model of amaeobiasis, z-VAD was demonstrated to
reduce the mean liver size by 70% at 24 hours compared
to the control group [43].
The neuroprotective proof of concept, using high
doses of Epo during a stroke, was applied to a parasitic
feature, cerebral malaria, a complex disorder with many
similarities to neurological stroke [67]. During cerebral
malaria, reduced cerebral blood flow is the pathological
consequence of microcirculation obstruction by infected
red blood cell sequestration [68].
Recently, the first evidence for neuroprotective adju-
vant therapy using Epo was provided in a murine model
of cerebral malaria: an artesunate - erythropoietin drug
combination led to an increase in the global survival
rate compared to artesunate monotherapy and to a clin-
ical recovery 24 hours earlier for surviving mice [69,70].
Wiese’s study confirmed these results and demonstrated
that recombinant erythropoietin increases survival in
mice with CM in a dose and time dependent manner
[28]. This effect could be mediated by neuronal apopto-
sis reduction: Epo reduced the mean number of TUNEL
+ neurons counted in the sagittal sections from both
brain hemispheres. Treatment with Epo was able to
decrease significantly IL-1b, TNFa and IFNg. It could
also be speculated that Epo’s effect is related to a reduc-
tion in the production of pro-inflammatory cytokines.
Another rationale for Epo adjunctive therapy during
cerebral malaria was recently provided by the demon-
stration in African children with human cerebral malaria
that high levels of Epo are associated with protection
against neurological sequelae [71]. In this context, an
open-labelled study, including children presenting with
very severe malaria with a Blantyre coma score below 3,
was conducted in Mali [72]. The objective was to assess
the short-term safety (seven days) of erythropoietin at
high doses (1,500 U/kg/day during three days) combined
with quinine. 35 patients with unrousable coma were
included in the study. None of the expected side effects
of erythropoietin were observed during the seven days
follow-up. No significant increase in the case fatality
rate (7/35 patients) was observed compared with other
studies with mortality rates ranging from 16 to 22% in
similar endemic areas. These data provide the first evi-
dence of the short-term safety of erythropoietin at high
doses combined with quinine. A multicenter study is
needed to assess the potential of Epo as an adjunctive
therapy to increase survival during cerebral malaria.
Taken together, these demonstrations are leading
towards new opportunities for cerebral malaria adjuvant
therapy in the near future. However, there is a main
drawback related to Epo use in a clinical setting due to
its potential for blood mass increase, although this is
rarely associated with thrombosis. No evidence of this
side effect was reported during Ehrenreich’s proof of
concept study using 33 000 IU/day of Epo during stroke.
This is in accordance with our results obtained in chil-
dren suffering from cerebral malaria and most of the
time admitted to hospital with severe anaemia. In this
context, compounds having Epo’s neuroprotective prop-
erties but without haematological side effects could be
an exciting alternative [73].
Other cytoprotective strategies have been tested
against parasitic diseases. Glatiramer, an immunomodu-
latory and potentially neuroprotective drug, was shown
to lead to lower risk for developing cerebral malaria in
treated animals. No direct neuroprotective effect such as
inhibition of apoptosis was found, but lower interferon
gamma levels were demonstrated in treated animals
[74]. This effect could be related to glatiramer-increased
anti-inflammatory type II monocytes and glatiramer reg-
ulatory T cells promotion, as demonstrated in a model
of multiple sclerosis [75]. Fasudil is a Rho kinase inhibi-
tor known to improve endothelial function through the
eNOS anti-apoptotic pathway: this drug has a potential
for restoration of endothelial barrier integrity after
human lung endothelial cell exposure to PRBCs in vitro
[11]. z-VAD, a caspase inhibitor, was successfully tested
in a Chagas model: this drug led to prevention of lym-
phocytes apoptosis and reduction of parasitemia through
type 1 immune response promotion [76].
From these studies, we can clearly identify promising
drugs that could be candidates for anti-apoptotic adju-
vant treatment in parasitic diseases. Even if these models
are not reproducing all the features of human infections,
they can predict most of the drug’s positive and negative
effects. Thus, evidence obtained from animals could
open new areas of translational research, working from
experimental evidence to clinical settings. Some of these
candidates are registered drugs used for many years in
humans. In those cases, translation from experimental
data to a clinical setting can be accelerated. Despite the
availability of safety profiles for these registered drugs,
unexpected side effects need to be carefully monitored
as they would be for a known drug in a new disease
setting.
There is a need to explore these anti-apoptotic adju-
vant treatments in parasitic diseases. These new thera-
peutic opportunities could contribute to the reduction
of the unacceptable high mortality rates associated with
these diseases.
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